With the regulatory review date firmly fixed in the calendar for December 1 and only four weeks to go, investors might be expected to be getting excited by the prospect of approval for Somaxon Pharmaceuticals’ sleep treatment Silenor.
But it might not be all plain sailing for Somaxon thanks to a study involving heart rates that the company under its own volition started, and one that some in the market believe could delay approval of the company's one and only drug in development by up to six months.
This content is written, edited and published by EP Vantage and is distributed by EvaluatePharma Ltd. All queries regarding the content should be directed to: news@epvantage.com
EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.
Drawing on EvaluatePharma, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.